MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

CureVac NV

Abierto

3.36 5

Resumen

Variación precio

24h

Actual

Mínimo

3.19

Máximo

3.38

Métricas clave

By Trading Economics

Ingresos

-409M

-39M

Ventas

-479M

14M

P/B

Media del Sector

3.915

57.333

BPA

-0.156

Margen de beneficio

-266.508

Empleados

825

EBITDA

-410M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+63.09% upside

Dividendos

By Dow Jones

Próximas Ganancias

22 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-14M

723M

Apertura anterior

-1.64

Cierre anterior

3.36

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

CureVac NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 jul 2024, 09:14 UTC

Adquisiciones, fusiones, absorciones

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3 jul 2024, 14:18 UTC

Adquisiciones, fusiones, absorciones

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 jul 2024, 09:38 UTC

Charlas de Mercado

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Comparación entre iguales

Cambio de precio

CureVac NV Esperado

Precio Objetivo

By TipRanks

63.09% repunte

Estimación a 12 meses

Media 5.17 USD  63.09%

Máximo 10 USD

Mínimo 2.5 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CureVac NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

1

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

3.19 / 3.27Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.